Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival.
Multiple myeloma (MM) is a progressive disease that is thought to result from multiple genetic insults to the precursor plasma cell that ultimately affords the tumor cell with proliferative potential despite its differentiated phenotype and resistance to undergoing apoptosis. Altered expression of antiapoptotic factors as well as growth factors have been described in a significant number of pat...
متن کاملImmunotherapy for Multiple Myeloma
1Clinic for Stem Cell Transplantation, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany 2 Service d’Hématologie Clinique, Hôpital Hôtel-Dieu, CHU de Nantes, Place Alexis Ricordeau, 44093 Nantes Cedex, France 3Hematology and Bone Marrow Transplantation, Internal Medicine, Chaim Sheba Medical Center, 52621 Tel-Hashomer, Israel 4Department o...
متن کاملImmunotherapy in Multiple Myeloma
The treatment of multiple myeloma has evolved significantly over the past decades, spanning from alkylator-based therapy to the more recent novel therapies that include proteasome inhibition and immunomodulatory agents. The introduction of immunotherapy to the treatment landscape of multiple myeloma has led to the development of new strategies and therapies that engage the immune system to enha...
متن کاملImmunotherapy Strategies Against Multiple Myeloma
Multiple myeloma is a monoclonal B-cell malignancy characterized by an accumulation of malignant plasma cells in the bone marrow, the presence of a monoclonal protein in the serum and/or urine, decreased normal immunoglobulin levels, and lytic bone disease. Patients with multiple myeloma benefit from combination therapy including novel therapeutic agents followed by autologous stem cell transpl...
متن کاملGenetically targeted radiotherapy for multiple myeloma.
Multiple myeloma is a disseminated neoplasm of terminally differentiated plasma cells that is incurable with currently available therapies. Although the disease is radiosensitive, external beam radiation leads to significant toxicity due to sensitive end-organ damage. Thus, genetic approaches for therapy are required. We hypothesized that the incorporation of immunoglobulin promoter and enhance...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 2019
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood-2019-128689